- Home
- CHNR vs MBIO Comparison
CHNR vs MBIO Comparison
Compare CHNR & MBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CHNR | MBIO |
|---|---|---|
| Founded | N/A | 2015 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Precious Metals | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.1M | 4.7M |
| IPO Year | 1995 | N/A |
Fundamental Metrics
Financial Performance| Metric | CHNR | MBIO |
|---|---|---|
| Price | $3.49 | $1.09 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 15.8K | ★ 90.3K |
| Earning Date | 12-31-2025 | 11-07-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.16 | $0.89 |
| 52 Week High | $8.20 | $13.29 |
Technical Indicators
Market Signals| Indicator | CHNR | MBIO |
|---|---|---|
| Relative Strength Index (RSI) | 39.90 | 46.83 |
| Support Level | $3.43 | $0.92 |
| Resistance Level | $3.82 | $1.15 |
| Average True Range (ATR) | 0.17 | 0.07 |
| MACD | -0.01 | 0.01 |
| Stochastic Oscillator | 15.12 | 68.00 |
Price Performance
Historical ComparisonAbout CHNR China Natural Resources Inc.
China Natural Resources Inc is engaged in exploration for lead, silver, and other metals in the Inner Mongolia Autonomous Region of the PRC and exploration of attractive opportunities in other sectors. The company has a single operating segment: exploration and mining.
About MBIO Mustang Bio Inc.
Mustang Bio Inc is a clinical-stage biopharmaceutical company focused on translating today's medical breakthroughs in cell and gene therapy into potential cures for hematologic cancers, solid tumors, and rare genetic diseases. Its pipeline is currently focused on the core areas of gene therapies for rare genetic disorders, chimeric antigen receptor (CAR) engineered T cell (CAR T) therapies for hematologic malignancies, and CAR T therapies for solid tumors.